Ginkgo Bioworks Shares Decline Post Q4 2025 Financial Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy DNA?
Source: Benzinga
- Strategic Shift: In its Q4 2025 financial report, Ginkgo Bioworks announced a pivot towards robotics and AI, with CEO Jason Kelly highlighting collaborations with the Department of Energy and OpenAI, aiming to enhance the company's competitiveness in emerging technologies.
- Divestiture Plan: The company plans to sell its biosecurity business for a minority stake to a consortium of investors, with the transaction expected to close in the first half of 2026, allowing Ginkgo to concentrate resources on its autonomous labs initiative and enhance core business growth potential.
- Market Reaction: Following the financial report, Ginkgo Bioworks shares fell by 24.7%, currently trading at $7.31, which is 18.13% and 12.5% below its 20-day and 100-day simple moving averages, indicating market concerns regarding the company's future prospects.
- Analyst Ratings: While William Blair analysts believe the company is moving in the right direction, they maintain an Underperform rating, citing challenges due to low visibility and transparency, with an average price target of $169.73.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.750
Low
12.00
Averages
12.00
High
12.00
Current: 6.750
Low
12.00
Averages
12.00
High
12.00
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Ginkgo Bioworks Stock Falls After Earnings Miss and Shift to Robotics Focus
- Earnings Miss: Ginkgo Bioworks' recent earnings report revealed a revenue miss, leading to a stock price decline that reflects market concerns about its future growth potential.
- Sales Decline: The reported sales figures fell short of analyst expectations, indicating that weak customer demand in the current market environment could hinder revenue growth.
- Strategic Shift: Ginkgo Bioworks is transitioning towards autonomous labs and robotics, aiming to enhance operational efficiency to tackle market challenges, although this shift may increase costs in the short term.
- Market Reaction: Investor response to the company's strategic shift has been cautious, as the stock price drop suggests a lack of confidence in the new strategy, which could impact future financing and investor relations.
See More
Ginkgo Bioworks Q4 Revenue Misses Expectations
- Revenue Decline: Ginkgo Bioworks reported Q4 revenue of $33 million, a 24.7% year-over-year decline that missed expectations by $4.57 million, indicating significant pressure in the competitive landscape.
- Cell Engineering Revenue Drop: The Q4 2025 cell engineering revenue was $26 million, down 26% from $35 million in the prior year, reflecting weakened customer demand and increasing market challenges.
- Biosecurity Revenue Decrease: Biosecurity revenue for Q4 was $7 million, down from $9 million in the same period last year, suggesting that growth potential in this area has not been realized, which may impact future investment decisions.
- Improved Net Loss: Although the GAAP net loss for Q4 was $81 million, an improvement from $108 million in the prior year, the adjusted EBITDA remained negative at $36 million, indicating ongoing efforts to control operating costs.
See More
Ginkgo Bioworks Shares Decline Post Q4 2025 Financial Report
- Strategic Shift: In its Q4 2025 financial report, Ginkgo Bioworks announced a pivot towards robotics and AI, with CEO Jason Kelly highlighting collaborations with the Department of Energy and OpenAI, aiming to enhance the company's competitiveness in emerging technologies.
- Divestiture Plan: The company plans to sell its biosecurity business for a minority stake to a consortium of investors, with the transaction expected to close in the first half of 2026, allowing Ginkgo to concentrate resources on its autonomous labs initiative and enhance core business growth potential.
- Market Reaction: Following the financial report, Ginkgo Bioworks shares fell by 24.7%, currently trading at $7.31, which is 18.13% and 12.5% below its 20-day and 100-day simple moving averages, indicating market concerns regarding the company's future prospects.
- Analyst Ratings: While William Blair analysts believe the company is moving in the right direction, they maintain an Underperform rating, citing challenges due to low visibility and transparency, with an average price target of $169.73.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Ginkgo Bioworks Updates on Q4 2025 Financial Results
- Financial Overview: Ginkgo Bioworks reported a net loss of $312.8 million for Q4 2025, an improvement from $547 million in Q4 2024, indicating efforts in cost control and operational optimization, although the overall financial situation remains challenging.
- Biosecurity Business Divestiture: The company announced the sale of its biosecurity business to a consortium of investors, expected to complete in the first half of 2026, allowing the biosecurity unit to operate independently, enhancing its flexibility and resource acquisition to accelerate growth.
- Focus on Autonomous Labs: Ginkgo plans to concentrate investments in the autonomous labs sector, with CEO Jason Kelly highlighting the rising interest in robotics and AI, which is expected to significantly enhance the company's value in laboratory research and drive future revenue growth.
- Future Outlook and Strategy: Ginkgo anticipates continued challenges in 2026, despite plans to optimize resource allocation through the divestiture of the biosecurity business, focusing on investments in autonomous labs to achieve long-term growth objectives.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Ginkgo Bioworks Stock Falls After Earnings Miss and Shift to Robotics Focus
- Earnings Miss: Ginkgo Bioworks' recent earnings report revealed a revenue miss, leading to a stock price decline that reflects market concerns about its future growth potential.
- Sales Decline: The reported sales figures fell short of analyst expectations, indicating that weak customer demand in the current market environment could hinder revenue growth.
- Strategic Shift: Ginkgo Bioworks is transitioning towards autonomous labs and robotics, aiming to enhance operational efficiency to tackle market challenges, although this shift may increase costs in the short term.
- Market Reaction: Investor response to the company's strategic shift has been cautious, as the stock price drop suggests a lack of confidence in the new strategy, which could impact future financing and investor relations.
See More
Ginkgo Bioworks Q4 Revenue Misses Expectations
- Revenue Decline: Ginkgo Bioworks reported Q4 revenue of $33 million, a 24.7% year-over-year decline that missed expectations by $4.57 million, indicating significant pressure in the competitive landscape.
- Cell Engineering Revenue Drop: The Q4 2025 cell engineering revenue was $26 million, down 26% from $35 million in the prior year, reflecting weakened customer demand and increasing market challenges.
- Biosecurity Revenue Decrease: Biosecurity revenue for Q4 was $7 million, down from $9 million in the same period last year, suggesting that growth potential in this area has not been realized, which may impact future investment decisions.
- Improved Net Loss: Although the GAAP net loss for Q4 was $81 million, an improvement from $108 million in the prior year, the adjusted EBITDA remained negative at $36 million, indicating ongoing efforts to control operating costs.
See More
Ginkgo Bioworks Shares Decline Post Q4 2025 Financial Report
- Strategic Shift: In its Q4 2025 financial report, Ginkgo Bioworks announced a pivot towards robotics and AI, with CEO Jason Kelly highlighting collaborations with the Department of Energy and OpenAI, aiming to enhance the company's competitiveness in emerging technologies.
- Divestiture Plan: The company plans to sell its biosecurity business for a minority stake to a consortium of investors, with the transaction expected to close in the first half of 2026, allowing Ginkgo to concentrate resources on its autonomous labs initiative and enhance core business growth potential.
- Market Reaction: Following the financial report, Ginkgo Bioworks shares fell by 24.7%, currently trading at $7.31, which is 18.13% and 12.5% below its 20-day and 100-day simple moving averages, indicating market concerns regarding the company's future prospects.
- Analyst Ratings: While William Blair analysts believe the company is moving in the right direction, they maintain an Underperform rating, citing challenges due to low visibility and transparency, with an average price target of $169.73.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Ginkgo Bioworks Updates on Q4 2025 Financial Results
- Financial Overview: Ginkgo Bioworks reported a net loss of $312.8 million for Q4 2025, an improvement from $547 million in Q4 2024, indicating efforts in cost control and operational optimization, although the overall financial situation remains challenging.
- Biosecurity Business Divestiture: The company announced the sale of its biosecurity business to a consortium of investors, expected to complete in the first half of 2026, allowing the biosecurity unit to operate independently, enhancing its flexibility and resource acquisition to accelerate growth.
- Focus on Autonomous Labs: Ginkgo plans to concentrate investments in the autonomous labs sector, with CEO Jason Kelly highlighting the rising interest in robotics and AI, which is expected to significantly enhance the company's value in laboratory research and drive future revenue growth.
- Future Outlook and Strategy: Ginkgo anticipates continued challenges in 2026, despite plans to optimize resource allocation through the divestiture of the biosecurity business, focusing on investments in autonomous labs to achieve long-term growth objectives.
See More
